CAPPS, A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Tramadol HCl/Acetaminophen for the Treatment of Painful Diabetic Neuropathy Sponsor      Ortho-McNeil Pharmaceutical Inc. Berman Center Investigator      Site Principal Investigator: William David, MD, PhD Berman Center Site Coordinator      Shirley Conn, RN, 612-341-7907 Description The objective of this study is to compare the analgesic efficacy and safety of tramadol HCl and acetaminophen versus placebo for the treatment of painful diabetic neuropathy. ACCORD, Action to Control Cardiovascular Risk in Diabetes      Substudies: ACCORD-Mind and ACCORD-Eye Sponsor and Initiator      National Heart Lung and Blood Institute (NHLBI), U.S. National Institutes of Health (NIH) Minnesota/Iowa Network Principal Investigators      Richard Bergenstal, MD, Minnesota International Diabetes Center      Richard Grimm, MD, PhD, Berman Center for Outcomes and Clinical Research Minnesota/Iowa Network Project Manager      Brenda Kirpach, CCRA, Berman Center for Outcomes and Clinical Research Description This trial addresses the challenges to cardiovascular health of persons with type 2 diabetes by testing three complementary medical treatment strategies. Participants are randomly assigned to a treatment regimen involving either aggressive or standard control of blood sugar. Then, depending on their blood pressure and cholesterol levels, they are assigned to either a blood pressure intervention or blood fat intervention. ORIGIN, Outcome Reduction with Initial Glargine Intervention Sponsor      Aventis Principal Investigator for U.S. Regional Coordinating Center      Jeffery Probstfield, MD, University of Washington School of Medicine Co-Principal Investigators      Hertzel Gerstein, MD, Professor of Medicine and Chief of Division of Endocrinology      McMaster University Faculty of Health Sciences, Hamilton, Ontario, Canada      Salim Yusuf, MD, Professor of Medicine and Chief of Division of Cardiology      McMaster University Faculty of Health Sciences, Hamilton, Ontario, Canada Berman Center Co-Investigators      Sidney A. Jones, MD, Hennepin Faculty Associates Division of Endocrinology, Diabetes, and Metabolism      Sandra Graham, NP Description ORIGIN is a 2x2 factorial study investigating the prevention of cardiovascular morbidity and mortality in people with type II diabetes, impaired glucose tolerance, and/or fasting glucose ≥110 mg/dL. The two factors are insulin glargine (Lantus) (variable dose vs. standard care), and omega-3 fatty acid (865mg vs. placebo). Participants are randomized to one of the four possible treatment combinations. DREAM, Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication Sponsor      Aventis Principal Investigator for U.S. Regional Coordinating Center      Jeffery Probstfield, MD, University of Washington School of Medicine Co-Principal Investigators      Hertzel Gerstein, MD, Professor of Medicine and Chief of Division of Endocrinology      McMaster University Faculty of Health Sciences, Hamilton, Ontario, Canada      Salim Yusuf, MD, Professor of Medicine and Chief of Division of Cardiology      McMaster University Faculty of Health Sciences, Hamilton, Ontario, Canada Berman Center Investigator      Sarah Kempainen, MD Berman Center Coordinator      Sandra Graham, NP, 612-341-7923 Description DREAM is an international, multi-center, randomized, double-blinded, placebo-controlled trial involving 4,000 participants at high risk for developing type II diabetes mellitus. Participants receive ramipril (ACE-I) or placebo and rosiglitazone (TZD) or placebo (therefore, there are 4 treatment combinations possible). The goal is to determine which group has a lower prospective incidence of DM. The study also collects observational data useful for establishing epidemiological associations between cardiovascular disease and type II diabetes mellitus.